17 October 2016 - PHARMAC is seeking feedback on a proposal to list alglucosidase alfa (Myozyme), idursulfase (Elaprase), and laronidase (Aldurazyme) for rare enzyme deficiency disorders, resulting from a provisional agreement formed between Sanofi-Aventis and PHARMAC.

The provisional agreement is the sixth that PHARMAC has reached with a bidder in a Request for Proposals we ran in 2014, related to the supply of medicines for rare disorders.

In summary, this proposal would result in three enzyme replacement therapies being funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions for the following indications:

• alglucosidase alfa (Myozyme) for patients with infantile Pompe disease from 1 December 2016;
  
• idursulfase (Elaprase) for patients with Hunter syndrome receiving a haematopoietic stem cell transplant from 1 December 2016; and
  
• laronidase (Aldurazyme) for patients with Hurler syndrome receiving a haematopoietic stem cell transplant. Listing in the Pharmaceutical Schedule would occur following Medsafe approval of the pharmaceutical.
  

Read PHARMAC press release